Risedronate shown to be safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicenter study

被引：0
|
作者：
Boonen, S.
Delmas, P. D.
Wenderoth, D.
Stoner, K. J.
Eusebio, R.
Orwoll, E. S.
机构：
[1] Katholieke Univ Leuven Hosp, Louvain, Belgium
[2] INSERM, Res Unit 403, F-69008 Lyon, France
[3] Procter & Gamble Pharmaceut, Schwalbach, Germany
[4] Procter & Gamble Pharmaceut, Mason, OH USA
[5] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S230 / S231
页数：2
相关论文
共 50 条
  • [1] Risedronate is safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicenter study
    Boonen, S.
    Delmas, P. D.
    Wenderoth, D.
    Stoner, K. J.
    Eusebio, R.
    Orwoll, E. S.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S119 - S119
  • [2] Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study
    Boonen, Steven
    Orwoll, Eric S.
    Wenderoth, Dietrich
    Stoner, Karen J.
    Eusebio, Rachelle
    Delmas, Pierre D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (04) : 719 - 725
  • [3] Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study
    Boonen, Steven
    Lorenc, Roman S.
    Wenderoth, Dietrich
    Stoner, Karen J.
    Eusebio, Rachelle
    Orwoll, Eric S.
    BONE, 2012, 51 (03) : 383 - 388
  • [4] Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial
    Greenspan, Susan L.
    Brufsky, Adam
    Lembersky, Barry C.
    Bhattacharya, Rajib
    Vujevich, Karen T.
    Perera, Subashan
    Sereika, Susan M.
    Vogel, Victor G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2644 - 2652
  • [5] SULFASALAZINE IN SPONDYLARTHROPATHY - A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    DOUGADOS, M
    VANDERLINDEN, S
    LEIRISALOREPO, M
    HUITFELDT, B
    BERTOUCH, J
    BROOKS, P
    DIJKMANS, B
    EDMONDS, J
    MAJOR, G
    KVIEN, T
    OLIVIERI, I
    VEYS, E
    ZEIDLER, H
    AMOR, B
    CALIN, A
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S92 - S92
  • [6] POSTMENOPAUSAL OSTEOPOROSIS - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
    STEVENSON, JC
    LEES, B
    ELLERINGTON, MC
    WHITCROFT, SIJ
    MARSH, MS
    WHITEHEAD, MI
    JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 : S325 - S325
  • [7] A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-YEAR TRIAL TO STUDY THE EFFECT OF NITRENDIPINE ON CHRONIC RENAL-TRANSPLANT FUNCTION
    BARENBROCK, M
    COLMORGEN, U
    FIRSCHKA, E
    GELLERT, J
    LIPPERT, J
    SCHRODER, K
    SPIEKER, C
    VOIGTLADNER, G
    WAGNER, K
    NEUMAYER, HH
    RAHN, KH
    CLINICAL NEPHROLOGY, 1995, 43 (06) : 388 - 391
  • [8] A 2-YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF AN ORAL SELECTIVE INOS INHIBITOR IN SUBJECTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEE
    le Graverand-Gastineau, M. -P. Hellio
    Clemmer, R.
    Redifer, P.
    Brunell, R. M.
    Hayes, C. W.
    Brandt, K.
    Abramson, S. B.
    Manning, P. T.
    Miller, C. G.
    Vignon, E.
    OSTEOARTHRITIS AND CARTILAGE, 2012, 20 : S38 - S38
  • [9] Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study
    Therese F. Nielsen
    Pernille Ravn
    Yu Z. Bagger
    Lise Warming
    Claus Christiansen
    Osteoporosis International, 2004, 15 : 168 - 174
  • [10] Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study
    Nielsen, TF
    Ravn, P
    Bagger, YZ
    Warming, L
    Christiansen, C
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (02) : 168 - 174
12345